Skip to main content

PLCB1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5.

Be the first to review this product! Submit a review

Images

Western blot - Human Plcb1 (Phospholipase C beta 1) knockout HeLa cell line (AB266033), expandable thumbnail
  • Sanger Sequencing - Human Plcb1 (Phospholipase C beta 1) knockout HeLa cell line (AB266033), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5

Alternative names

1 phosphatidylinositol 4,5 bisphosphate phosphodiesterase beta 1, 1-phosphatidyl-D-myo-inositol-4,5-bisphosphate, 1-phosphatidylinositol-4, 5-bisphosphate phosphodiesterase beta-1, EIEE12, Inositoltrisphosphohydrolase, Monophosphatidylinositol phosphodiesterase, PI PLC, PLC 1, PLC-154, PLC-I, PLC-beta-1, PLCB1_HUMAN, Phosphb, Phosphoinositidase C, Phosphoinositide phospholipase C, Phosphoinositide phospholipase C-beta-1, Phospholipase C beta 1 (phosphoinositide-specific), Phospholipase C-I, Phospholipase C-beta-1, Plcb1 protein, Triphosphoinositide phosphodiesterase

Recommended products

PLCB1 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, Homozygous: 1 bp insertion in exon 5
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
PLCB1
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Zygosity
Homozygous

Quality control

STR analysis
CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level
EU: 2 US: 2
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

Phospholipase C beta 1 (PLCB1) also known as PLC-β1 or PLCB1 is an enzyme involved in intracellular signal transduction. With a molecular weight of around 150 kDa PLCB1 hydrolyzes phosphatidylinositol 45-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). This biochemical activity plays an important role in the release of calcium ions from intracellular stores. PLCB1 is expressed in regions of the brain including the cerebral cortex as well as in other tissues.

Biological function summary

Multiple functions depend on the signaling cascades initiated by PLCB1. It belongs to a larger family of phospholipase C enzymes contributing to the regulation of various neural processes. The enzyme acts within multiprotein complexes that modulate intracellular calcium levels influencing neuronal activity and synaptic transmission. This role implicates PLCB1 in modulating brain functions related to learning and memory.

Pathways

PLCB1 contributes to cellular signaling pathways such as the phosphoinositide signaling pathway and the G protein-coupled receptor (GPCR) pathway. In these pathways PLCB1 interacts with major proteins such as Gαq subunit of G proteins which activates it. These interactions place PLCB1 as a central player in the pathways that help convert extracellular signals into intracellular actions often involving the regulation of secondary messengers like IP3 and DAG.

Associated diseases and disorders

Researchers associate PLCB1 with neurological and psychiatric conditions including epilepsy and bipolar disorder. Dysregulation in PLCB1 activity links to altered calcium signaling which can affect brain function. Additionally proteins like Gαq and other GPCR pathway elements may either buffer or exacerbate effects arising from PLCB1 anomalies suggesting molecular interdependencies in related disease mechanisms.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com